Huatai Securities Reports Record 2024 Earnings and Advancement in Internationalization
HONG KONG SAR - Media OutReach Newswire - 31 March 2025 - Huatai Securities Co., Ltd. (the 'Company"; stock codes: 601688.SH, 6886.HK, HTSC.L), a leading technology-driven comprehensive securities company in China, released its consolidated financial results for the year ended December 31, 2024, reporting record revenue and profit, alongside substantial progress in its internationalization strategy.
Annual Highlights：
In 2024, the Company continued to execute on strategic priorities, contributing to net revenues of RMB 54.29 billion, net earnings of RMB 15.35 billion, and diluted EPS of RMB 1.62, achieving the highest results for each.
The Company announced a final payout of RMB 5.2 per 10 shares (including tax), reinforcing its commitment to shareholder value.
The investment banking business led the Mainland market, ranking first in STAR Market and ChiNext IPOs, and first in M&A activities.
The Company expanded its presence in Singapore, Japan, Vietnam, leveraging operations across Mainland China, Hong Kong, the US, the UK, and Singapore.
The Company drove growth across its comprehensive financial services, including investment banking, wealth management, and institutional services, through technology-driven initiatives.
The Company made significant progress in the following areas:
Investment Banking Excellence
The preeminent global investment banking business leveraged industry insights and deep expertise to help clients seize new opportunities, unlocking growth and driving transformation. Ranked first in IPO underwriting on the STAR Market and ChiNext, Huatai Securities achieved a total IPO underwriting volume of RMB 8.5 billion, ranking second in the A-share market. The Company maintained a leading position in M&A advisory, particularly in restructuring project reviews. Additionally, it secured second place in equity underwriting with RMB 54.9 billion and achieved third place in bond underwriting, with a total volume of RMB 1,296 billion. In 2024, the Company ranked third in the total number of Hong Kong IPOs across the market and third among Chinese securities firms in terms of funds raised.
Huatai Securities solidified its leading position in China's capital markets by supporting innovation-driven enterprises. Since 2012, the Company has been a critical catalyst for technological innovation, backing over 270 technology companies with a collectively market capitalization of RMB 9.47 trillion. In 2024, this commitment continued with support for over 10 'Little Giants' and specialized medium-sized enterprises endorsed by China's Ministry of Industry and Information Technology.
Global Reach Accelerates
Huatai Securities expanded its international footprint in 2024, demonstrating resilience in navigating volatile overseas markets. Huatai Financial Holdings (Hong Kong) became a lead underwriter in Tokyo's PRO-BOND market, while Huatai Securities (USA) gained Nasdaq underwriting membership. Additionally, a subsidiary of Huatai International, operating as a Chinese securities firm, successfully obtained a securities trading license in Vietnam.
The Company's Global Trading Platform (GTP) now connects Hong Kong, the U.S., the U.K., and Singapore 24/7, enhancing cross-border capabilities. Research output surged, with 587 overseas reports (up 96% year-on-year) covering U.S., European, Japanese, and Southeast Asian markets, and stock coverage increased by 65%.
Advancing Through Technology
To meet the evolving demands of institutional clients, Huatai Securities continued upgrading core trading infrastructure such as FICC HEAD platform and CAMS (Credit Analysis Management System). The tech-powered transformation enabled the Company to lead in market-making in the STAR Market with 126 stocks and fund liquidity services with 589 funds, while dual-counter RMB-HKD trading achieved full coverage and increased market share. The Company was awarded '2024 Top Market Maker – RMB Counter' by HKEX.
On the retail front, 'ZhangLe Fortune Path' app, the Company's mobile wealth management platform, is deepening AI integration to enhance client services, delivering sophisticated ETF tools for product selection and trading strategies, thereby boosting client and asset growth. Huatai Securities' fund distribution ranked second among securities firms, with AUM of equity fund reaching RMB 120.2 billion. The Huatai-PineBridge CSI 300 ETF approached RMB 360 billion, leading non-money-market ETFs in Shanghai and Shenzhen.
Sustainability and Governance
Huatai Securities' MSCI ESG rating rose to AAA in 2024, the highest among global investment banks, up from AA, marking two years of steady progress. Through its Huatai Foundation, rated 5A in Jiangsu's social organization assessment, the Company advanced rural revitalization, education, and eco-initiatives such as 'One Yangtze River', promoting Other Effective Area-Based Conservation Measures (OECM) in China, which were presented at COP16.
Looking Ahead
Huatai Securities will continue its strategic focus on leveraging technology to enhance its wealth management and institutional services. By integrating resources across the business chain, the Company will further deepen its internationalization strategy, aiming to become one of the leading global investment banks providing top-tier professional financial services.
Hashtag: #Huatai
The issuer is solely responsible for the content of this announcement.
About Huatai Securities
Incorporated in April 1991, Huatai Securities is a leading technology-driven securities group in China, with a highly collaborative business model, a cutting-edge digital platform and an extensive and engaging customer base. It provides comprehensive financial services to individual and institutional clients, including wealth management, investment banking, sales and trading, investment management, among others, with a substantial international presence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
15 minutes ago
- Associated Press
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. 'Pharvaris embraced the opportunity to engage in scientific exchange with the HAE thought leader community during EAACI as we presented data supporting the differentiated profile of deucrictibant for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks,' said Berndt Modig, Chief Executive Officer of Pharvaris. 'Building on our R&D call from last week, we shared data demonstrating the potential for deucrictibant to address the unmet needs of people living with bradykinin-mediated angioedema beyond HAE-1/2. Deucrictibant showed sustained attack reduction and improved quality of life measures in the randomized portion of the CHAPTER-1 study, which was maintained in the open-label extension study, as well as early-onset symptom relief and complete symptom resolution in a single dose in most attacks in our ongoing RAPIDe-2 on-demand long-term extension RAPIDe-3 is the first and only phase 3 on-demand study that will explore 'end-of-progression' as a new pre-specified endpoint, which is particularly meaningful for people living with HAE. Together with the outcomes from other study endpoints, we will be able to assess the full impact of deucrictibant on an HAE attack from start to end.' Details of the presentations are outlined below: Prophylaxis Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study, a poster presentation by Emel Aygören-Pürsün, M.D. Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study, a flash talk by Markus Magerl, M.D. CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks, a flash talk by William Lumry, M.D. Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone, an oral presentation by Laurence Bouillet, M.D., Ph.D. On-Demand Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study, a thematic poster session by Henriette Farkas, M.D., Ph.D., Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study, a flash talk by Anna Valerieva, M.D., Ph.D. Expansion Beyond HAE Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema, a flash talk by Evangelia Pardali, Ph.D. Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency, a thematic poster session by Andrea Zanichelli, M.D., Ph.D. The posters are available on the Investors section of the Pharvaris website at: About Deucrictibant Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration and orphan designation by the European Commission. About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit Forward Looking Statements This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words 'believe,' 'anticipate,' 'expect,' 'estimate,' 'may,' 'could,' 'should,' 'would,' 'will,' 'intend' and similar expressions. These forward-looking statements are based on management's current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris' actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the outcome and timing of regulatory approvals; the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; political conditions, such as the current war between Russia and Ukraine; economic conditions, including continuing inflation concerns; and the other factors described under the headings 'Cautionary Statement Regarding Forward-Looking Statements' and 'Item 3. Key Information—D. Risk Factors' in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris' views as of any date subsequent to the date of this press release. Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [email protected]
Associated Press
15 minutes ago
- Associated Press
VEON Announces USD 35 Million Share Buyback
Announcement marks the third phase of USD 100 million share buyback program Dubai, June 16, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator ('VEON' or the 'Company'), announces that it will shortly commence the third phase of its previously announced share buyback program with respect to the Company's American Depositary Shares ('ADSs'). This third phase of the buyback will be in the amount of up to USD 35 million. The third phase of the share buyback program is being launched after the successful completion of the second phase on May 21, 2025. Cumulatively, the two earlier phases of the program have resulted in the repurchase of 1.43 million ADSs at an average repurchase price of USD 45.59 per ADS. VEON had announced a share buyback program of up to USD 100 million on August 1, 2024. The Company continues to believe that its ADSs are undervalued relative to its operational performance and strategic potential. With the buyback program, VEON aims to optimize shareholder value and strengthen its financial position for future opportunities. The buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18. VEON is also considering options to raise external financing through a sub-benchmark private placement of bonds, with a tenor of up to approximately four years (the 'Notes'), with the goal of supporting the Company's strategic initiatives and enhancing its financial flexibility. The Notes, if issued, will be issued by VEON Midco B.V. and guaranteed by VEON Amsterdam B.V. This evaluation is a part of VEON's ongoing capital planning effort and discussions with potential institutional investors are in progress. About VEON VEON is a digital operator that provides connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world's population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ and headquartered in Dubai. For more information visit: No Offer or Solicitation ADS Buyback This press release shall not constitute an offer to buy ADSs nor the solicitation of an offer to sell ADSs. The ADS buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18. Private Placement Transaction This press release is neither an offer to sell nor the solicitation of an offer to buy the Notes or any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which, or to any person to whom, such an offer, solicitation or sale is unlawful. The offering of Notes described in this press release has not been and will not be registered under U.S. securities laws or the securities laws of any other jurisdiction and, accordingly, the offer or sale of these securities (if any) may be made only in a transaction exempt from the registration requirements of the U.S. Securities Act and any other applicable securities laws. There will be no public offering of the Notes in the United States. The Notes will be offered (if at all) in the European Economic Area and in the UK only to persons who are not retail investors. Forward-Looking Statements This release contains 'forward-looking statements,' as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to the initiation and continuation of the third phase of the Company's share buyback program, the proposed transactions, including any Notes private placement offering, the expected timing of completing the proposed transactions and the expected impact of the proposed transactions. These statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause VEON's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of, or failure to consummate, the ADS buyback or any Notes private placement; the outcome of any legal proceedings that may be instituted against VEON Ltd. or others; and other risks and uncertainties set forth in the Company's and its subsidiaries' filings. Forward-looking statements are inherently subject to risks and uncertainties, many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update, except as required by U.S. federal securities laws, any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events. No assurances can be made that the parties will successfully complete the transactions described in this press release. Contact Information Communications [email protected] Investor Relations [email protected]
Yahoo
18 minutes ago
- Yahoo
Renault CEO's Resignation Throws Fragile Turnaround Into Doubt
(Bloomberg) -- Renault SA's impending loss of Chief Executive Officer Luca de Meo calls into question the French carmaker's brittle restoration, with the board having to replace a second senior leader in a matter of months. Shuttered NY College Has Alumni Fighting Over Its Future Do World's Fairs Still Matter? As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space NYC Renters Brace for Price Hikes After Broker-Fee Ban As American Architects Gather in Boston, Retrofits Are All the Rage De Meo will step down July 15, Renault announced late Sunday, sending its shares tumbling as much as 8% at the open Monday in Paris. His resignation closely follows the exit of Thierry Piéton, the former chief financial officer who left for medical-device maker Medtronic Plc in March. The departure amounts to a major setback for a carmaker that's been recovering despite substantial challenges facing the global auto industry, including an uncertain transition to electric vehicles, escalating trade tensions and the rise of increasingly competitive Chinese manufacturers. De Meo, 58, will join Gucci owner Kering SA, according to people familiar with the matter. 'It's clearly good news for Kering and a bad one for Renault,' said Enguerrand Artaz, a fund manager at La Financière de l'Echiquier. 'This move could potentially undermine its strategy.' Renault shares traded down 6.7% as of 12:30 p.m. in Paris, while Kering's stock jumped 9.5%. Renault's lineup was 'completely transformed' under De Meo, Stephen Reitman, an equity analyst at Bernstein with the equivalent of a buy rating on the stock, wrote to clients. He called the CEO's departure a shock and 'unequivocally a blow to Renault.' De Meo told investors back in February that the company was working on a new midterm plan to reinforce new offerings including the Renault 5 electric city car and Dacia Bigster sport utility vehicle. The CEO built up a China-based engineering team and talked up prospects for a budding partnership with Zhejiang Geely Holding Group Co. What Bloomberg Intelligence Says The reported departure of Renault CEO Luca de Meo for Kering is a loss after he engineered a major turnaround for the automaker from its pandemic-era crisis, and which still faces rising price competition, stagnant demand in Europe and a costly EV shift. — Michael Dean, BI senior auto industry analyst Click here for the research Renault was in crisis when De Meo took over in mid-2020, coming off a record first-half loss and having announced plans to slash almost 15,000 jobs. Even after Russia's invasion of Ukraine prompted the manufacturer to pull out of what had been its second-biggest market, Renault has vastly outperformed longtime alliance partner Nissan Motor Co. The two have been paring back their partnership and agreed in March to reduce their cross-shareholdings to 10%, from 15% previously. Bloomberg News reported last month that Nissan was looking to sell some of its stake in Renault as part of broader plans to raise more than ¥1 trillion ($6.9 billion). De Meo's departure 'leaves Renault leaderless at a time when the group is due to communicate a new strategic plan and further unwind the Nissan alliance,' Philippe Houchois, a Jefferies analyst with a holding rating on the stock, wrote in a report. Renault's board will aim to pick De Meo's successor before the CEO leaves in mid-July, according to a person familiar with the matter, who asked not to be identified because the plan hasn't been announced. The French government will participate in the search for a new CEO, a finance ministry official said. The French state is Renault's largest shareholder, owning a 15% stake. American Mid: Hampton Inn's Good-Enough Formula for World Domination The Spying Scandal Rocking the World of HR Software New Grads Join Worst Entry-Level Job Market in Years As Companies Abandon Climate Pledges, Is There a Silver Lining? The $7 Billion Nicotine-Pouch Market's Next Target? Women ©2025 Bloomberg L.P.
